Spectral Medical Full Year 2022 Earnings: Beats Expectations

Spectral Medical (TSE:EDT) Full Year 2022 Results

Key Financial Results

• Revenue: CA$1.67m (down 19% from FY 2021).
• Net loss: CA$7.60m (loss narrowed by 14% from FY 2021).
• CA$0.028 loss per share (improved from CA$0.035 loss in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Spectral Medical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 99% p.a. on average during the next 3 years, compared to a 71% growth forecast for the Biotechs industry in Canada.

Performance of the Canadian Biotechs industry.

The company's shares are down 7.4% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 5 warning signs for Spectral Medical you should be aware of, and 2 of them are a bit concerning.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.